ReviewInternational journal of molecular sciences2017
Theranostic Biomarkers for Schizophrenia.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Oxytocin levels in individuals with schizophrenia are high in cerebrospinal fluid but low in serum: A systematic review and meta-analysis : Oxytocin and Schizophrenia.Metabolic brain disease · 2021Pooled it
- Association Between REELIN Gene Polymorphisms (rs7341475 and rs262355) and Risk of Schizophrenia: an Updated Meta-analysis.Journal of molecular neuroscience : MN · 2021Pooled it
- Digital and Biomarker-Based Monitoring for Schizophrenia-Treatment Adherence.Neuropsychopharmacology reports · 2026Review
- The Potential of Hair Matrix for Biomarker Analysis in Schizophrenia.International journal of molecular sciences · 2025Review
- Clinical, functional and salivary cortisol level changes in individuals with schizophrenia undergoing cognitive behavioral therapy for psychosis in addition to their usual antipsychotic medication.Comprehensive psychoneuroendocrinology · 2025Article
- Neuroendocrine characterization into schizophrenia: norepinephrine and melatonin as promising biomarkers.Frontiers in endocrinology · 2025Article
- Vagus nerve stimulation for epilepsy: A narrative review of factors predictive of response.Epilepsia · 2024Review
- An In Vitro Study for the Role of Schizophrenia-Related Potential miRNAs in the Regulation of COMT Gene.Molecular neurobiology · 2024Article
- Pharmaco-EEG of antipsychotic treatment response: a systematic review.Schizophrenia (Heidelberg, Germany) · 2023Review
- Cortisol and cytokines in schizophrenia: A scoping review.Comprehensive psychoneuroendocrinology · 2023Article
- Article
- Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system.Molecular diversity · 2023Review
- The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders.Advances in neurobiology · 2023Article
- Deviant spontaneous neural activity as a potential early-response predictor for therapeutic interventions in patients with schizophrenia.Frontiers in neuroscience · 2023Article
- Medication adherence among community-dwelling schizophrenia patients during the COVID-19 pandemic: A cross-sectional study.Psychiatry research · 2022Article
- Markers of Schizophrenia-A Critical Narrative Update.Journal of clinical medicine · 2022Review
- Article
- Genome-wide DNA methylation in an animal model and human studies of schizophrenia: a protocol for a meta-analysis.BMJ open science · 2022Article
- Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia.Frontiers in psychiatry · 2022Article
- Bioinformatics analysis of long non-coding RNA-associated competing endogenous RNA network in schizophrenia.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a highly heritable, chronic, severe, disabling neurodevelopmental brain disorder with a heterogeneous genetic and neurobiological background, which is still poorly understood. To allow better diagnostic procedures and therapeutic strategies in schizophrenia patients, use of easy accessible biomarkers is suggested. The most frequently used biomarkers in schizophrenia are those associated with the neuroimmune and neuroendocrine system, metabolism, different neurotransmitter systems and neurotrophic factors. However, there are still no validated and reliable biomarkers in clinical use for schizophrenia. This review will address potential biomarkers in schizophrenia. It will discuss biomarkers in schizophrenia and propose the use of specific blood-based panels that will include a set of markers associated with immune processes, metabolic disorders, and neuroendocrine/neurotrophin/neurotransmitter alterations. The combination of different markers, or complex multi-marker panels, might help in the discrimination of patients with different underlying pathologies and in the better classification of the more homogenous groups. Therefore, the development of the diagnostic, prognostic and theranostic biomarkers is an urgent and an unmet need in psychiatry, with the aim of improving diagnosis, therapy monitoring, prediction of treatment outcome and focus on the personal medicine approach in order to improve the quality of life in patients with schizophrenia and decrease health costs worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.